Peptic Ulcer Disease; Stomach and Gastric Ulcers, a Concise Review
Published: 2023-03-01
Page: 30-39
Issue: 2023 - Volume 6 [Issue 1]
Ahtshamullah Chaudhry *
St. Dominic Hospital, Jackson, Mississippi, United States.
Kimberly Morton Cuthrell
Saint James School of Medicine, United States.
Owen R Thornton
University of North Carolina at Chapel Hill, United States.
*Author to whom correspondence should be addressed.
Abstract
The most prevalent condition affecting the stomach and duodenum is peptic ulcer disease (PUD), which is linked to Helicobacter pylori (H. pylori) infection. Esophageal, duodenal, and stomach ulcers are all parts of peptic ulcer disease (PUD). Epigastric discomfort is the PUD symptom that commonly occurs. Proton Pump Inhibitors (PPI), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and antibiotics are widely used to treat PUD, which is caused by an imbalance between offensive and defensive forces. Abdominal discomfort, nausea, vomiting, weight loss, and bleeding or perforation with the complicated disease areonly a few of the symptoms of peptic ulcer disease. Understanding the methodology behind diagnosis and treatment options requires identifying the risk factors and mechanisms that result in PUD. The purpose of this review is to provide a concise summary of key ideas and recent findings in the field of peptic ulcer disease management, etiology, pathophysiology, and epidemiology.
Keywords: Ulcer disease, stomach, gastric ulcers, proton pump inhibitors (PPI)
How to Cite
Downloads
References
Sanad MH, Saleh GM, Marzook FA. Radioiodination and biological evaluation of nizatidine as a new highly selective radiotracer for peptic ulcer disorder detection. J Labelled Comp Radiopharm. 2017;60(13):600-607.
Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management. Elsevier Health Sciences; 2020.
Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017;390(10094):613-624.
Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health. 1996;86(2):200-5.
Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 2007; 76(7):1005-12.
Nieto YB. Protocolo terapéutico de la úlcera péptica. Medicine-Programa de Formación Médica Continuada Acreditado. 2012;11(3):179-182.
Sung JJ, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol. 2010;105(1): 84-9.
Martins LC, et al. Soroprevalência de anticorpos contra o antígeno CagA do Helicobacter pylori em pacientes com úlcera gástrica na região Norte do Brasil. Revista da Sociedade Brasileira de Medicina Tropical. 2002;35:307-310.
Lafortuna CL, et al. The relationship between body composition and muscle power output in men and women with obesity. J Endocrinol Invest. 2004; 27(9):854-61.
Toneto MG, Oliveira FJM, Lopes MHI. Evolução histórica da úlcera péptica: da etiologia ao tratamento. Scientia Medica. 2011;21(1):23-30.
Sonnenberg, A, Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther. 2013;38(4):329-42.
Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf. 2017;16(6):673-685.
Kayali S, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89(8-s):72-76.
Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137-46.
Johnson Alegbeleye B. A modified open omental plugging of peptic ulcer perforation in a mission hospital, northwestern cameroon. Journal of Clinical Investigation and Studies. 2019; 2(1).
Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol. 2005;11(25):3811-6.
Zhang BB, et al. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Molecular Biology Reports. 2014;41:7241-7254.
Ayoub F, et al. Once versus twice-daily oral proton pump inhibitor therapy for prevention of peptic ulcer rebleeding: A propensity score-matched analysis. Gastroenterology Res. 2018; 11(3):200-206.
Chey WD, Wong BC. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-25.
Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14-22.
Lanas Á, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol, 2015;13(5):906-12.e2.
Somasundaram S, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther, 2000;14(5):639-50.
Masclee GM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-792.e9; quiz e13-4.
Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology. 2013;144(7):1384-93, 1393.e1-2; quiz e18-9.
González-Pérez, A, et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One. 2014;9(7): e101768.
Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Official Journal of the American College of Gastroenterology| ACG. 2017;112(2):212-239.
Kanno T, et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. J Gastroenterol. 2015;50(1):31-40.
Kiss, S, et al, Helicobacter‐negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis. Alimentary Pharmacology & Therapeutics. 2016;43(8): 924-932.
McColl KE. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am. 2009;38(2):353-61.
El-Omar EM, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997; 113(1):15-24.
Moss, S.F, et al, Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet, 1992;340(8825): 930-2.
Bhala N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 2013;382(9894):769-79.
Bjarnason I, et al. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther. 2007;26(1):95-106.
Mössner J. The indications, applications, and risks of proton pump inhibitors. Dtsch Arztebl Int. 2016;113(27-28):477-83.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. The Lancet. 2002;359(9300):14-22.
Charpignon C, et al. Peptic ulcer disease: one in five is related to neither H elicobacter pylori nor aspirin/NSAID intake. Alimentary Pharmacology & Therapeutics. 2013;38(8):946-954.
Levenstein S, et al. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clinical Gastroenterology and Hepatology. 2015;13(3):498-506. e1.
McColl KE. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterology Clinics of North America. 2009;38(2):353-361.
Agréus L, Talley NJ, Jones M. Value of the “test & treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter. 2016;21(3):186-191.
Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756-80.
Siddique O, et al. Helicobacter pylori infection: An Update for the internist in the age of increasing global antibiotic resistance. Am J Med. 2018;131(5):473-479.
Hooi JKY, et al. Global prevalence of Helicobacter pylori infection: Systematic Review and meta-analysis. Gastroenterology. 2017;153(2):420-429.
Zaki M, et al. H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol. 2013;304(8):G715-22.
Scida S, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed. 2018;89(8-s):40-43.
Barchi A, et al. A non-invasive method for the diagnosis of upper GI diseases. Acta Biomed. 2018;89(8-s):40-43.
Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019; 24(1):e12554.
Buysse T, Kotwal V. Gastric outlet obstruction caused by a duodenal clot. Cureus. 2022;14(3):e22814.
Malfertheiner P, et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report. Gut. 2017;66(1):6-30.
Park JY, et al. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig Dis Sci. 2016;61(8):2373-2380.
Lanas AI, et al. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995; 109(4):1124-33.
Lanas A, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther. 2011;33(5):585-91.
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017; 11(1):27-37.
Stanley AJ, et al. Multicentre comparison of the glasgow blatchford and rockall scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage. Aliment Pharmacol Ther. 2011;34(4):470-5.
Villanueva C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21.
Laine L, Jensen DM. Management of patients with ulcer bleeding. Official Journal of the American College of Gastroenterology| ACG. 2012;107(3):345-360.
Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-62.
Wang CH, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(9):751-8.
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345-60; quiz 361.
Lanas A, Chan FKL. Peptic ulcer disease. The Lancet. 2017;390(10094): 613-624.
Kuna L, et al. Peptic Ulcer disease: a brief review of conventional therapy and herbal treatment options. Journal of Clinical Medicine. 2019;8(2):179.
Søreide K, et al. Perforated peptic ulcer. The Lancet. 2015;386(10000):1288-1298.
Zhang BB, et al. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep. 2014; 41(11):7241-54.
De DD, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World Journal of Gastroenterology: WJG. 2015;21(10): 2883.
Lanas Á, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clinical Gastroenterology and Hepatology. 2015;13(5):906-912. e2.
Masclee GM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-792. e9.